The Financial Impact of a Continuous Bioprocessing Strategy

April 11, 2023

Joseph Shultz, VP and technical head of biologics and vaccines at Resilience, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss the financial considerations biopharma companies face when implementing a continuous strategy. Shultz talks about the mindset of the senior leadership at Amgen—and then Novartis—that lead to the eventual adoption of a new bioprocessing system and how their strategies benefit multiple teams within a single organization. He also discusses the importance of setting key milestones to track successes and failures, the business parameters best suited for continuous bioprocessing, and the real and imagined hurdles associated with continuous over batch processing.

GUEST BIO

Joseph Schultz, VP and Technical Head of Biologics and Vaccines, Resilience
Joseph Schultz is the VP and technical head of biologics and vaccines at Resilience. Previously, Joseph led teams at Novartis and Amgen building factories of the future.

MODERATOR BIO

John Bonham-Carter, Board Member and VP of Business Development and Product Management, Erbi Biosystems
John Bonham-Carter is recognized as one of the early pioneers in making continuous bioprocessing a manufacturing reality. Leveraging the ATF System technology developed at Refine Technology (acquired by Repligen in 2014), Bonham-Carter helped forge the future of intensified processing, ensuring that all processes could benefit from exceptionally high productivity processes. To date, 20+ therapeutic products, from vaccines to gene therapies and proteins, are now commercially manufactured with products that Bonham-Carter brought to market. He is sought after as a technically focused expert to bring new technologies to market and has been a regular international speaker and co-organizer of several cell culture conferences.